Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics, Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shanghai, China. Key agenda items include the re-election of directors, approval of the company’s financial statements, and authorization for share buybacks, which could impact the company’s market operations and shareholder value.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc., incorporated in the Cayman Islands, operates in the biopharmaceutical industry. The company focuses on the development, manufacturing, and commercialization of high-quality biologics for the treatment of oncology, autoimmune, and other major diseases.
YTD Price Performance: 69.26%
Average Trading Volume: 21,465,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.2B
Find detailed analytics on 1801 stock on TipRanks’ Stock Analysis page.